Literature DB >> 11267265

Interleukin-6 in chronic renal allograft rejection: influence of nonimmunologic risk factors.

M Boratyńska1, M Klinger, P Szyber, D Patrzalek, K Polak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11267265     DOI： 10.1016/s0041-1345(00)02393-9

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

1.  Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Authors:  Birgit Fogal; Tai Yi; Chen Wang; Deepak A Rao; Amir Lebastchi; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

2.  SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function.

Authors:  Lingfeng Qin; Qunhua Huang; Haifeng Zhang; Renjing Liu; George Tellides; Wang Min; Luyang Yu
Journal:  J Am Coll Cardiol       Date:  2013-08-28       Impact factor: 24.094

3.  Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.

Authors:  Chen Wang; Tai Yi; Lingfeng Qin; Roberto A Maldonado; Ulrich H von Andrian; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

4.  The Oxidative and Inflammatory State in Patients with Acute Renal Graft Dysfunction Treated with Tacrolimus.

Authors:  Sandra Carrillo-Ibarra; José Ignacio Cerrillos-Gutiérrez; Ariadna Escalante-Núñez; Enrique Rojas-Campos; Benjamín Gómez-Navarro; Sonia Sifuentes-Franco; Ernesto Germán Cardona-Muñoz; Alejandra Guillermina Miranda-Díaz
Journal:  Oxid Med Cell Longev       Date:  2016-10-30       Impact factor: 6.543
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.